Welcome to
RBP World!
Drugs target to IL6
| Drug name | Drug type | Disease/phenotype | Mechanism of action(MoA) | Phase | Status | Source |
|---|---|---|---|---|---|---|
| CLAZAKIZUMAB | Antibody | Cachexia | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLOKIZUMAB | Antibody | COVID-19 | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLOKIZUMAB | Antibody | rheumatoid arthritis | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| OLOKIZUMAB | Antibody | COVID-19 | Interleukin-6 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| SILTUXIMAB | Antibody | monoclonal gammopathy | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| SILTUXIMAB | Antibody | COVID-19 | Interleukin-6 inhibitor | 3.0 | Completed | ClinicalTrials |
| SILTUXIMAB | Antibody | pancreatic adenocarcinoma | Interleukin-6 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SIRUKUMAB | Antibody | temporal arteritis | Interleukin-6 inhibitor | 3.0 | Terminated | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | asthma | Interleukin-6 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | psoriatic arthritis | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| ZILTIVEKIMAB | Antibody | chronic kidney disease | Interleukin-6 binding agent | 1.0 | Completed | ClinicalTrials |
| SILTUXIMAB | Antibody | prostate carcinoma | Interleukin-6 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SIRUKUMAB | Antibody | polymyalgia rheumatica | Interleukin-6 inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| SILTUXIMAB | Antibody | schizophrenia | Interleukin-6 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SILTUXIMAB | Antibody | Castleman disease | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLOKIZUMAB | Antibody | COVID-19 | Interleukin-6 inhibitor | 3.0 | Recruiting | ClinicalTrials |
| SILTUXIMAB | Antibody | leukemia | Interleukin-6 inhibitor | 0.5 | Recruiting | ClinicalTrials |
| SILTUXIMAB | Antibody | myelodysplastic syndrome | Interleukin-6 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SILTUXIMAB | Antibody | type 1 diabetes mellitus | Interleukin-6 inhibitor | 0.5 | Completed | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | COVID-19 | Interleukin-6 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SIRUKUMAB | Antibody | cutaneous lupus erythematosus | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| SIRUKUMAB | Antibody | COVID-19 | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLOKIZUMAB | Antibody | rheumatoid arthritis | Interleukin-6 inhibitor | 2.0 | Terminated | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | COVID-19 | Interleukin-6 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SILTUXIMAB | Antibody | multiple myeloma | Interleukin-6 inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| SILTUXIMAB | Antibody | Giant Lymph Node Hyperplasia | Interleukin-6 inhibitor | 4.0 | - | DailyMed |
| MRA 003 US | Antibody | systemic lupus erythematosus | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| SIRUKUMAB | Antibody | rheumatoid arthritis | Interleukin-6 inhibitor | 3.0 | Completed | ClinicalTrials |
| SILTUXIMAB | Antibody | Castleman disease | Interleukin-6 inhibitor | 2.0 | Terminated | ClinicalTrials |
| ZILTIVEKIMAB | Antibody | anemia (phenotype) | Interleukin-6 binding agent | 1.0 | Completed | ClinicalTrials |
| SIRUKUMAB | Antibody | asthma | Interleukin-6 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | acute graft vs. host disease | Interleukin-6 inhibitor | 1.0 | Terminated | ClinicalTrials |
| SIRUKUMAB | Antibody | rheumatoid arthritis | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLOKIZUMAB | Antibody | rheumatoid arthritis | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| ZILTIVEKIMAB | Antibody | heart failure | Interleukin-6 binding agent | 3.0 | Not yet recruiting | ClinicalTrials |
| SILTUXIMAB | Antibody | COVID-19 | Interleukin-6 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | rheumatoid arthritis | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| SILTUXIMAB | Antibody | renal cell carcinoma | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| SILTUXIMAB | Antibody | multiple myeloma | Interleukin-6 inhibitor | 1.0 | Terminated | ClinicalTrials |
| SIRUKUMAB | Antibody | rheumatoid arthritis | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | COVID-19 | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| SIRUKUMAB | Antibody | immune system disease | Interleukin-6 inhibitor | 3.0 | - | ATC |
| OLOKIZUMAB | Antibody | rheumatoid arthritis | Interleukin-6 inhibitor | 3.0 | Completed | ClinicalTrials |
| OLOKIZUMAB | Antibody | Crohn's disease | Interleukin-6 inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | acute graft vs. host disease | Interleukin-6 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SILTUXIMAB | Antibody | prostate cancer | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| PF-04236921 | Antibody | systemic lupus erythematosus | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| SILTUXIMAB | Antibody | multiple myeloma | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| PF-04236921 | Antibody | Crohn's disease | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| MEDI-5117 | Antibody | rheumatoid arthritis | Interleukin-6 inhibitor | 1.0 | Terminated | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | Fatigue | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| OLOKIZUMAB | Antibody | osteoarthritis | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| SILTUXIMAB | Antibody | multiple myeloma | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| SIRUKUMAB | Antibody | systemic lupus erythematosus | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| SIRUKUMAB | Antibody | major depressive disorder | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| SILTUXIMAB | Antibody | prostate adenocarcinoma | Interleukin-6 inhibitor | 1.0 | Completed | ClinicalTrials |
| SIRUKUMAB | Antibody | lupus nephritis | Interleukin-6 inhibitor | 2.0 | Completed | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | oral mucositis | Interleukin-6 inhibitor | 2.0 | Terminated | ClinicalTrials |
| CLAZAKIZUMAB | Antibody | Crohn's disease | Interleukin-6 inhibitor | 2.0 | Terminated | ClinicalTrials |
| SILTUXIMAB | Antibody | immune system disease | Interleukin-6 inhibitor | 4.0 | - | ATC |
| SILTUXIMAB | Antibody | kidney cancer | Interleukin-6 inhibitor | 2.0 | Withdrawn | ClinicalTrials |